The diabetes drug Mounjaro and the obesity treatment Zepbound brought in nearly $8.7 billion and $4.2 billion, respectively, reflecting the consumers' ongoing "love affair" with GLP-1 drugs
Given the escalating global prevalence of these diseases, there is an unprecedented opportunity to expand the global market for GLP-1RAs
Figure 1 Figure 2 The discovery of the second incretin, GLP-1, originated from observations in 1982 that anglerfish proglucagon mRNA contained coding sequences of glucagon-related peptide, flanked by pairs of basic amino acids characteristic of the sites cleaved during post-translational processing of prohormones ( Figure 1 Section A]
Fourth, discrepancies in outcome datasuch as mismatched sample sizes and overlapping datasets between discovery and replication phases due to FinnGencompromised the validity of their conclusions
Weak compounds are being selected out
the returns affect you and everyone around you, forever," Asprey says.